Physician profile
Nicholas R Lemming
NPI 1427033562
$6,025.24
in general payments reported to CMS, 2019-2025
36 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $260 · 2021: $728 · 2022: $781 · 2023: $1,006 · 2024: $1,044 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,887 · Education: $38.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.07 |
| Education | $38.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $858.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $850.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $772.09 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $523.83 | 2020-2025 | Bevespi Aerosphere, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $462.93 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $338.97 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.45 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $246.08 | 2019-2025 | |
| Pfizer INC. | $171.07 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.24 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $146.01 | 2019-2023 | Eliquis |
| Boston Scientific Corporation | $135.26 | 2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $132.53 | 2019 | |
| Amgen INC. | $107.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.14 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.42 | 2020-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $66.30 | 2019-2023 | |
| Abbott Laboratories | $59.22 | 2021-2025 | Freestyle Libre 3 |
| Eisai INC. | $57.35 | 2021 | |
| Sanofi Pasteur INC. | $49.96 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $46.95 | 2024 | Rexulti |
| Allergan, INC. | $38.96 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.79 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.94 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $29.83 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $29.68 | 2021 | |
| Antares Pharma, INC. | $28.55 | 2022-2025 | Xyosted |
| Neurocrine Biosciences, INC. | $25.79 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $22.71 | 2019 | |
| Dexcom, INC. | $21.24 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $19.11 | 2022 | |
| Amarin Pharma, INC. | $17.22 | 2021 | |
| Astellas Pharma US INC | $16.97 | 2021 | |
| Lundbeck LLC | $15.94 | 2025 | Rexulti |
| Medtronic, INC. | $13.11 | 2022 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lemming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.